SuperworthInspireMD NSPR
- Market cap
- $20.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $10.8M
- +53% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −203.3%
InspireMD trades at 1.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $10.8M over the last twelve months, up 53% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.6M+9% | $1.8M+72% | $1.5M+22% | $1.7M+6% | $1.8M+16% | $1.9M+11% | $1.5M+1% | $1.8M+2% | $2.5M+39% | $3.1M+62% | $3.4M+122% | $1.8M−0% | |
| Cost of revenue | $1.1M+5% | $1.3M+52% | $1.2M+41% | $1.4M+22% | $1.4M+25% | $1.5M+18% | $1.2M+2% | $1.5M+4% | $1.7M+19% | $2M+33% | $2.7M+119% | $2.5M+74% |
| Gross profit | $438K+20% | $505K+155% | $292K−22% | $331K−33% | $414K−6% | $469K−7% | $292K+0% | $313K−5% | $864K+109% | $1.2M+152% | $687K+135% | −$774K |
| R&D | $2.1M+2% | $2M+1% | $2.6M+42% | $3.4M+71% | $3.9M+86% | $3.7M+82% | $4.1M+55% | $3.8M+13% | $3.6M−7% | $3.5M−6% | $4.8M+17% | $4.3M+12% |
| SG&A | $4M+36% | $4.3M+37% | $5.1M+75% | $5.2M+36% | $5M+25% | $6.1M+44% | $7.7M+51% | $9.5M+83% | $10.3M+107% | $9.8M+59% | $9.9M+29% | $9.4M−1% |
| −$5.6M+22% | −$5.8M+18% | −$7.4M+69% | −$8.3M+55% | −$8.5M+50% | −$9.4M+61% | −$11.5M+55% | −$13M+58% | −$13.1M+54% | −$12.1M+29% | −$14M+22% | −$14.4M+11% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$5.2M+14% | −$5.4M+12% | −$7M+65% | −$7.9M+56% | −$7.9M+52% | −$9.2M+70% | −$11.2M+59% | −$13.2M+66% | −$12.7M+61% | −$11.8M+28% | −$13.7M+23% | −$14.3M+9% |
| −$0.15−74% | −$0.16−73% | −$0.21−60% | −$0.22−8% | −$0.16+7% | −$0.19+19% | $0.22 | −$0.26+18% | −$0.17+6% | −$0.14−26% | −$0.16 | −$0.17−35% | |
| 34M+334% | 33.5M+317% | 34.2M+323% | 35.9M+70% | 48.4M+42% | 49.4M+47% | 50M+46% | 51M+42% | 73.5M+52% | 82.4M+67% | 83.8M+68% | 84.7M+66% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest InspireMD's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NSPRInspireMD | $20.9M | n/m | n/a | 1.9× | +53% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| Peer median | $75.8M | 14.3× | 15.7× | 1.4× | +11% | 7.6% |
More on InspireMD
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .